a. BIOTRONIK data on file (n = 5), based on statistically significant differences on the bench for Pushability, Trackability, and Crossability compared to Xience Skypoint, superior to Xience in STEMI patients; 1. Iglesias JF. et al, Long-term outcomes with biodegradable polymer sirolimus eluting stents versus durable polymer everolimus-eluting stents in ST-segment elevation myocardial infarction: 5-year follow-up of the BIOSTEMI randomized superiority trial, The Lancet, 2024; 2. In comparison to Xience Sierra, Resolute Onyx and Synergy for bench tests on pushability, trackability and crossability, BIOTRONIK data on file; 3. As characterized with respect to strut thickness in Bangalore et al. Meta-analysis; 4. Based on investigator’s interpretation of BIOFLOW-V primary endpoint results.

Clinical data collected with the Orsiro DES device within the Orsiro family clinical program.

Orsiro and Orsiro Mission are trademarks or registered trademarks of the BIOTRONIK Group of Companies. All other trademarks are the property of their respective owners.

© 2025 BIOTRONIK AG – All rights reserved.
Specifications are subject to modification, revision and improvement.